contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


invitation-to-the-presentation-of-alks-annual-report-2024-on-wednesday-19-february-2025

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

AlK-Abelló är verksamt inom läkemedelsbranschen. Bolaget är en utvecklare av allergi- och immunterapi. Verksamhet innehas på global nivå och produkterna säljs både som vaccin och i tablettform. En stor del av verksamheten fokuserar mot forskning och utveckling inom nämnt arbetsområde, där bolaget aktivt arbetar med diagnostisering och behandling av återkommande allergibesvär. Bolaget grundades 1923 och har sitt huvudkontor i Hørsholm, Danmark.

ALK-Abelló

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors...

ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CET, where ALK’s management will comment on the results and outlook and be available for questions. ALK will be represented by Peter Halling, President &amp; CEO, Claus Steensen Sølje, CFO and Per Plotnikof, VP, Head of IR.&nbsp; Live audio webcast The meeting will be audio webcasted live and be available for replay on <a href="https://www.globenewswire.com/Tracker?data=29-lA4BVrXB3zXjy-N1yiuUbS2k9dEQ-RSVChqde8BMuLzd0TfghIRoMo-jXc6qoYLXxOIgZJtxOCk91sAkaYg==">ALK’s website</a>. Conference call If you wish to participate via telephone, please register for the conference call by using this link: <a href="https://www.globenewswire.com/Tracker?data=Xo3LLQF1IWt_8_RbPUaJtQpBtsGk6mv5TlPlONhCQNbE9iyWxburMLVgu2VqiftvIIknx_cJuG5ezJnc7goByDC9okJjOkIlF6PVAkVSAPhBQgt1Ne3DNQa-Zk8pZkKIwGlxxm6CBZnrZy5ywVmYuKThnfJX2CfOJLlsN4OFiIs=">Registration - ALK FY 2024 - telephone conference</a> and follow the instructions. You will receive an email from <a href="https://www.globenewswire.com/Tracker?data=cthupybjjgUpJImEqOt_fEdKEmnIvuX1sxDswVyf96T3RxvlxdGh3-AOkHfr8VTnov1JUq_DOxZYhl_oxEdRpAebrfZlVgcaGzwDo3B_Pr417tSXJ9CKE6o-n_sBGXuA">diamondpass@choruscall.com</a> with dial-in details, including a passcode and a pin code. Please make sure to whitelist&nbsp;<a href="https://www.globenewswire.com/Tracker?data=cthupybjjgUpJImEqOt_fEdKEmnIvuX1sxDswVyf96RRzU6t05tHuWj3TD7qVFYf9TbKwvzJLoJvuEgrg05GeFX-B2Xk80Ph6xdno73NsHP1O38HmDfZJKa7zZvOcibW">diamondpass@choruscall.com</a> and/or check your spam filter. We advise you to register on the day before the call at the latest. Presentation The presentation will be available on <a href="https://www.globenewswire.com/Tracker?data=29-lA4BVrXB3zXjy-N1yilzj-1UVNBx1LsYMYbg8JvX8SfCJBNkPv8SbeB8qPsEigCBFXzXt1NNja00W3p6hqg==">ALK's website</a> shortly before the meeting starts. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALK ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. Attachment<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/032d98ec-1003-4eeb-9fdb-6c9d8c80c161">InvestorNews_12Feb25</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA0ODE2NSM0MDIwNTk2MjAjMjAwMjIzMQ==" alt=""> <img src="https://ml-eu.globenewswire.com/media/ZjU5ODc5NzgtZTUyOC00YjVlLTk1OWQtNDdhMDRlMzI2Mjc3LTEwMTM4MDQ=/tiny/ALK-Abello.png" alt="">

Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025